Glass House Brands (GLAS) Retained Earnings (2020 - 2026)
Glass House Brands' (GLAS) quarterly Retained Earnings came in at -$237.2 million in Q1 2026, down 18.32% year-on-year from -$290.4 million in Q1 2025, and down 7.78% on a QoQ basis from -$220.1 million in Q4 2025.
Glass House Brands (GLAS) Retained Earnings (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Retained Earnings data on file, last reported at -$237.2 million in Q1 2026.
- On a quarterly basis, Retained Earnings fell 18.32% year-over-year to -$237.2 million in Q1 2026; TTM through Mar 2026 was -$237.2 million, a 18.32% decrease from a year earlier, with the FY2025 full-year figure at -$220.1 million, down 15.58% from the prior year.
- Retained Earnings for Q1 2026 stood at -$237.2 million, down from -$220.1 million in the prior quarter.
- Over the last five years, Retained Earnings for GLAS reached as high as -$79.6 million in Q3 2022 and fell as low as -$237.2 million in Q1 2026.
- Historically, Retained Earnings has averaged -$167.6 million across 5 years, with a median of -$190.9 million in 2023.
- Across the five-year window, Retained Earnings slumped 1243.84% in 2022 and advanced 4.2% in 2025, its largest moves.
- Year by year, Retained Earnings stood at -$92.7 million in 2022, then slumped by 106.05% to -$190.9 million in 2023, then grew by 0.27% to -$190.4 million in 2024, then decreased by 15.58% to -$220.1 million in 2025, then declined by 7.78% to -$237.2 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$237.2 million in Q1 2026, -$220.1 million in Q4 2025, and -$204.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 8.83 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | -413.76 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | -237.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -237.21 Mn |
| Dec 31, 2025 | -220.08 Mn |
| Sep 30, 2025 | -204.10 Mn |
| Jun 30, 2025 | -191.81 Mn |
| Mar 31, 2025 | -200.48 Mn |
| Dec 31, 2024 | -190.42 Mn |
| Sep 30, 2024 | -202.52 Mn |
| Jun 30, 2024 | -199.27 Mn |
| Mar 31, 2024 | -209.27 Mn |
| Dec 31, 2023 | -190.94 Mn |
| Sep 30, 2023 | -160.37 Mn |
| Jun 30, 2023 | -160.10 Mn |
| Mar 31, 2023 | -135.09 Mn |
| Dec 31, 2022 | -92.67 Mn |
| Sep 30, 2022 | -79.62 Mn |
| Jun 30, 2022 | -94.80 Mn |
| Mar 31, 2022 | -80.63 Mn |
| Dec 31, 2021 | -59.76 Mn |
| Sep 30, 2021 | -42.26 Mn |
| Mar 31, 2021 | -6.00 Mn |